Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Gets Price Target Boost from Wells Fargo & Company

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target upped by analysts at Wells Fargo & Company from $18.00 to $19.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 12.13% from the stock’s previous close.

A number of other analysts have also issued reports on RARE. Citigroup boosted their target price on Ultragenyx Pharmaceutical from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, September 18th. Cantor Fitzgerald raised their target price on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a report on Friday, September 18th. Royal Bank Of Canada downgraded Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a report on Thursday, September 3rd. Canaccord Genuity Group boosted their price objective on shares of Ultragenyx Pharmaceutical from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Hold” and an average price target of $33.65.

Ultragenyx Pharmaceutical Trading Up 1.9%

RARE stock traded up $0.31 during trading on Wednesday, reaching $16.94. 1,068,572 shares of the stock were exchanged, compared to its average volume of 2,841,309. Ultragenyx Pharmaceutical has a 1 year low of $12.73 and a 1 year high of $39.89. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -2.89 and a beta of 0.37. The business has a 50 day moving average price of $16.64 and a 200-day moving average price of $22.81.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million during the quarter, compared to the consensus estimate of $182.49 million. The firm’s revenue was up 8.2% compared to the same quarter last year. During the same period last year, the business posted ($1.81) earnings per share. On average, research analysts anticipate that Ultragenyx Pharmaceutical will post -4.30 EPS for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the sale, the chief financial officer owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. The trade was a 7.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,510 shares of company stock valued at $127,561 in the last three months. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC purchased a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $661,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth about $76,000. Profund Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 49.4% during the third quarter. Profund Advisors LLC now owns 76,847 shares of the biopharmaceutical company’s stock worth $1,155,000 after buying an additional 25,397 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Ultragenyx Pharmaceutical by 14.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,989 shares of the biopharmaceutical company’s stock valued at $276,000 after acquiring an additional 2,314 shares during the last quarter. Finally, Sterling Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 102.4% in the third quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,252 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability guidance. It expects expense and workforce reductions to cut 2027 R&D spending by at least 50% compared with 2025. Ultragenyx third-quarter results and outlook
• Positive Sentiment: The company said it has agreements to sell two Priority Review Vouchers for a combined $413 million, providing a substantial source of cash. FDA approvals of GENGLYCOS and FAYUVI were also announced during the quarter. Ultragenyx third-quarter results and outlook
• Neutral Sentiment: Revenue rose 8.2% year over year to $173 million, including $109 million from CRYSVITA and $30 million from DOJOLVI. The quarterly loss narrowed to $1.16 per share from $1.81 a year earlier. Ultragenyx third-quarter earnings results
• Negative Sentiment: Despite year-over-year improvement, the $1.16 per-share loss was slightly wider than analysts’ roughly $1.10–$1.15 expected loss, and revenue of $173 million fell short of the $182.5 million consensus estimate. Ultragenyx Q3 loss and revenue results

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.